Literature DB >> 9554725

Do chemokines mediate leukocyte recruitment in post-traumatic CNS inflammation?

R M Ransohoff1, M Tani.   

Abstract

Hematogenous leukocytes infiltrate the CNS after inflammatory stimuli, including infection, mechanical trauma and excitotoxic neuronal necrosis. However,the role of leukocytic inflammation in promoting or hindering tissue repair is poorly understood. Identification of signals that lead to leukocyte recruitment and activation is essential for the designing of interventions that modulate inflammation, thus improving neurological outcome. Chemokines are small pleiotropic chemoattractant cytokines whose target specificity suggests an important role in determining the cellular composition of inflammatory infiltrates. Chemokine expression profiles in the CNS during autoimmune and post-traumatic inflammation correlate well with the composition of leukocyte infiltrates, and expression studies in systems such as transgenic mice, suggest that chemokines have potent functional attributes in CNS physiology. We propose that selective chemokine expression by CNS cells is crucial for post-traumatic leukocyte accumulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554725     DOI: 10.1016/s0166-2236(97)01198-3

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  33 in total

1.  Stat1-independent regulation of gene expression in response to IFN-gamma.

Authors:  C V Ramana; M P Gil; Y Han; R M Ransohoff; R D Schreiber; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

Review 2.  [The relevance of the inflammatory response in the injured brain].

Authors:  O I Schmidt; I Leinhase; E Hasenboehler; S J Morgan; P F Stahel
Journal:  Orthopade       Date:  2007-03       Impact factor: 1.087

Review 3.  Neurobiology of resilience in depression: immune and vascular insights from human and animal studies.

Authors:  Katarzyna A Dudek; Laurence Dion-Albert; Fernanda Neutzling Kaufmann; Ellen Tuck; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2019-09-13       Impact factor: 3.386

4.  Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits.

Authors:  R A Dumont; B D Car; N N Voitenok; U Junker; B Moser; O Zak; T O'Reilly
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 5.  Glucocorticoids and central nervous system inflammation.

Authors:  Klaus Dinkel; William O Ogle; Robert M Sapolsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

6.  Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain.

Authors:  Ji Zhang; Xiang Qun Shi; Stefania Echeverry; Jeffrey S Mogil; Yves De Koninck; Serge Rivest
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 7.  [Traumatic brain injury: impact on timing and modality of fracture care].

Authors:  P F Stahel; W Ertel; C E Heyde
Journal:  Orthopade       Date:  2005-09       Impact factor: 1.087

8.  MCP-1 involvement in glial differentiation of neuroprogenitor cells through APP signaling.

Authors:  Emmanuel George Vrotsos; Pappachan E Kolattukudy; Kiminobu Sugaya
Journal:  Brain Res Bull       Date:  2009-01-29       Impact factor: 4.077

9.  Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain.

Authors:  Imre Szabo; Xiao-Hong Chen; Li Xin; Martin W Adler; O M Z Howard; Joost J Oppenheim; Thomas J Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-18       Impact factor: 11.205

10.  Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis.

Authors:  Michael A Flierl; Philip F Stahel; Daniel Rittirsch; Markus Huber-Lang; Andreas D Niederbichler; L Marco Hoesel; Basel M Touban; Steven J Morgan; Wade R Smith; Peter A Ward; Kyros Ipaktchi
Journal:  Crit Care       Date:  2009-02-06       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.